165 related articles for article (PubMed ID: 11108882)
1. Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity.
Elger W; Bartley J; Schneider B; Kaufmann G; Schubert G; Chwalisz K
Steroids; 2000; 65(10-11):713-23. PubMed ID: 11108882
[TBL] [Abstract][Full Text] [Related]
2. Global gene expression profiling of progesterone receptor modulators in T47D cells provides a new classification system.
Afhüppe W; Sommer A; Müller J; Schwede W; Fuhrmann U; Möller C
J Steroid Biochem Mol Biol; 2009 Jan; 113(1-2):105-15. PubMed ID: 19130882
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of 11' imidazolyl antiprogestins and mesoprogestins.
Nickisch K; Elger W; Santhamma B; Garfield R; Killeen Z; Amelkina O; Schneider B; Meister R
Steroids; 2014 Dec; 92():45-55. PubMed ID: 25174783
[TBL] [Abstract][Full Text] [Related]
4. The use of progesterone antagonists for cervical ripening and as an adjunct to labour and delivery.
Chwalisz K
Hum Reprod; 1994 Jun; 9 Suppl 1():131-61. PubMed ID: 7962460
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium.
Chwalisz K; Brenner RM; Fuhrmann UU; Hess-Stumpp H; Elger W
Steroids; 2000; 65(10-11):741-51. PubMed ID: 11108885
[TBL] [Abstract][Full Text] [Related]
6. Progesterone receptor modulators and progesterone antagonists in women's health.
Spitz IM; Chwalisz K
Steroids; 2000; 65(10-11):807-15. PubMed ID: 11108892
[TBL] [Abstract][Full Text] [Related]
7. Next step in the development of mesoprogestins: the preclinical profile of EC313.
Błaszczak-Świątkiewicz K; Krupa A; Mnich E; Elger W; Oettel M; Nair H; Wierzbicki M; Sieroszewski P; Shaked Z
Front Endocrinol (Lausanne); 2023; 14():1201547. PubMed ID: 37766684
[TBL] [Abstract][Full Text] [Related]
8. The use of progesterone antagonists and progesterone receptor modulators in contraception.
Spitz IM; Van Look PF; Coelingh Bennink HJ
Steroids; 2000; 65(10-11):817-23. PubMed ID: 11108893
[TBL] [Abstract][Full Text] [Related]
9. Discovery, chemistry, and reproductive pharmacology of asoprisnil and related 11beta-benzaldoxime substituted selective progesterone receptor modulators (SPRMs).
Schubert G; Elger W; Kaufmann G; Schneider B; Reddersen G; Chwalisz K
Semin Reprod Med; 2005 Feb; 23(1):58-73. PubMed ID: 15714390
[TBL] [Abstract][Full Text] [Related]
10. Progesterone antagonists and progesterone receptor modulators: an overview.
Spitz IM
Steroids; 2003 Nov; 68(10-13):981-93. PubMed ID: 14667991
[TBL] [Abstract][Full Text] [Related]
11. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
Katkam RR; Gopalkrishnan K; Chwalisz K; Schillinger E; Puri CP
Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
[TBL] [Abstract][Full Text] [Related]
12. In vitro characterization of ZK 230211--A type III progesterone receptor antagonist with enhanced antiproliferative properties.
Afhüppe W; Beekman JM; Otto C; Korr D; Hoffmann J; Fuhrmann U; Möller C
J Steroid Biochem Mol Biol; 2010 Mar; 119(1-2):45-55. PubMed ID: 20043998
[TBL] [Abstract][Full Text] [Related]
13. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer.
Klijn JG; Setyono-Han B; Foekens JA
Steroids; 2000; 65(10-11):825-30. PubMed ID: 11108894
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a Tier I screening battery for detecting endocrine-active compounds (EACs) using the positive controls testosterone, coumestrol, progesterone, and RU486.
O'Connor JC; Davis LG; Frame SR; Cook JC
Toxicol Sci; 2000 Apr; 54(2):338-54. PubMed ID: 10774816
[TBL] [Abstract][Full Text] [Related]
15. Progestins, progesterone receptor modulators, and progesterone antagonists change VEGF release of endometrial cells in culture.
Classen-Linke I; Alfer J; Krusche CA; Chwalisz K; Rath W; Beier HM
Steroids; 2000; 65(10-11):763-71. PubMed ID: 11108887
[TBL] [Abstract][Full Text] [Related]
16. [Selective progesterone receptor modulators and their therapeutical use].
Driák D; Sehnal B; Svandová I
Ceska Gynekol; 2013 Apr; 78(2):175-81. PubMed ID: 23710982
[TBL] [Abstract][Full Text] [Related]
17. Endometrial and myometrial effects of progesterone antagonists in pregnant guinea pigs.
Elger W; Fähnrich M; Beier S; Qing SS; Chwalisz K
Am J Obstet Gynecol; 1987 Oct; 157(4 Pt 2):1065-74. PubMed ID: 3479025
[TBL] [Abstract][Full Text] [Related]
18. Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy.
DeManno D; Elger W; Garg R; Lee R; Schneider B; Hess-Stumpp H; Schubert G; Chwalisz K
Steroids; 2003 Nov; 68(10-13):1019-32. PubMed ID: 14667995
[TBL] [Abstract][Full Text] [Related]
19. Modulation of oestrogenic effects by progesterone antagonists in the rat uterus.
Chwalisz K; Stöckemann K; Fritzemeier KH; Fuhrmann U
Hum Reprod Update; 1998; 4(5):570-83. PubMed ID: 10027611
[TBL] [Abstract][Full Text] [Related]
20. Non-competitive anti-oestrogenic actions of progesterone antagonists in primate endometrium: enhancement of oestrogen and progesterone receptors with blockade of post-receptor proliferative mechanisms.
Neulen J; Williams RF; Breckwoldt M; Chwalisz K; Baulieu EE; Hodgen GD
Hum Reprod; 1996 Jul; 11(7):1533-7. PubMed ID: 8671500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
